Mass Tort brief
Strict Bottler Liability and Class Action Precedents
Israeli courts expand strict product liability for spontaneous failures and enforce 90% insurance payouts, while Teva faces bellwether generic drug trials.
Mass Tort
The Tel Aviv District Court hit Tempo with a ₪3.1M verdict — ruling that beverage bottlers bear strict liability whenever pressurized commercial bottles shatter.
BackgroundIsrael's Defective Products Liability Law of 1980 holds manufacturers strictly liable for bodily injuries caused by defective goods regardless of negligence. Beverage bottlers routinely argue that glass fractures stem from post-delivery mishandling or transit shocks rather than bottling flaws.
- Judge Idit Katzboy rejected Tempo's defense that it did not produce the glass itself, ruling that security footage proved the bottle exploded spontaneously without external impact.
- The court awarded ₪2.5M in personal injury damages and state insurance reimbursement, alongside ₪600,000 for legal expenses and court-appointed medical experts.
- The precedent dramatically increases liability exposure for Israeli beverage manufacturers, compelling bottlers to upgrade pressure-testing standards across commercial glass bottling lines.
Mass Tort
Menora settled a class action over denied heart attack claims — forcing the insurer to pay 90% compensation after relying on obsolete lab thresholds to reject policyholders.
BackgroundCritical illness insurance policies provide lump-sum payouts upon acute myocardial infarction based on clinical enzyme thresholds. Israeli hospital laboratories adopted high-sensitivity troponin assays years ago, but insurers continued enforcing older regulatory metrics to deny claims.
- The lawsuit established that Menora systematically denied cardiac claims by citing a superseded 2013 regulatory circular rather than contemporary hospital laboratory standards.
- Under the settlement terms, Menora will reopen past rejected cardiac files, providing 90% compensation payouts alongside full retroactive premium refunds to eligible policyholders.
- An independent medical review panel will adjudicate contested claims, establishing an enforceable benchmark that could force rival Israeli insurers to settle similar pending challenges.
Mass Tort
Flydubai passengers are mobilizing a $43.5M mass tort suit over an in-flight cockpit brawl — testing airline liability for severe psychological trauma under international aviation treaties.
BackgroundThe Montreal Convention governs commercial airline liability for passenger injuries and safety violations during international flights. Flight FZ1073 experienced sharp altitude swings and severe cockpit disruption approaching Ben Gurion Airport before landing safely.
- The passenger action committee is headed by Tzvika Manes, CEO of Bank Leumi's underwriting subsidiary, and plans to name Flydubai alongside Israeli and UAE aviation authorities.
- Attorneys estimate claims between $200,000 and $250,000 per passenger for acute mental distress and physical endangerment, seeking total damages reaching ₪160M.
- The case tests whether international aviation treaties permit substantial psychological trauma damages when passengers suffer terror from crew-induced turbulence without catastrophic physical impact.
Mass Tort
Teva's own admissions to the Justice Department have boxed in its civil defense — leaving the pharma giant exposed to multi-billion-dollar liabilities in upcoming generic price-fixing trials.
BackgroundMultidistrict Litigation 2724 in Pennsylvania consolidates antitrust suits from 48 US state attorneys general and private drug buyers alleging coordinated generic price-fixing. While Teva settled criminal charges with the US Department of Justice, civil liability claims remained open.
- A federal ruling holding Teva's deferred prosecution agreement as binding evidence strips the pharmaceutical company of key civil defenses ahead of jury selection.
- Simultaneously, US municipalities are passing formal resolutions allocating annual settlement tranches funded by Teva under its national $4.25B opioid master settlement.
- These price-fixing bellwethers represent Teva's final major unresolved legal overhang as Chief Executive Richard Francis redirects capital toward higher-margin innovative biopharmaceuticals.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
